AIM ImmunoTech Inc. (AIM) Stock
Healthcare · Biotechnology · Member of Other US Stocks
AIM ImmunoTech Inc. (AIM) closed at USD 0.16 on 2026-10-14, a change of -93.5 % over the past year, with a market capitalization of USD 6.79M.
AIM ImmunoTech Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 0.16 |
| 2026-10-13 | 0.17 |
| 2026-10-12 | 0.18 |
| 2026-10-09 | 0.18 |
| 2026-10-08 | 0.18 |
| 2026-10-07 | 0.18 |
| 2026-10-06 | 0.18 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
AIM ImmunoTech Inc. key figures
- Previous close
- USD 0.16 (2026-10-14)
- 1-year change
- -93.5 %
- Market cap
- USD 6.79M
- Enterprise value
- USD -858,703
- P/E ratio (trailing)
- -0.06
- P/E ratio (forward)
- -0.46
- EPS (trailing)
- -2.98
- EPS (forward)
- -0.37
- PEG ratio
- 0.71
- Price to book
- 0.64
- Revenue growth
- 4 %
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 0.12
- Employees
- 19
- Analyst consensus (third-party)
- none
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for AIM ImmunoTech Inc. and compare it with other stocks.
Analyze AIMAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell AIM ImmunoTech Inc. shares.